BOMBARDIER JOINS FORCES WITH THE BOMBARDIER, BEAUDOIN, AND FONTAINE FAMILIES TO OVERCOME NEUROLOGICAL DISEASES WITH A $2 MILLION DONATION Français
This donation will fund the CHUM's SERVO Project, which will provide a better understanding of neurological diseases to offer personalized treatments to patients
MONTREAL, Oct. 24, 2023 /CNW/ - The CHUM Foundation is pleased to announce that Bombardier, alongside with the Bombardier, Beaudoin and Fontaine families, are helping to fund the CHUM's SERVO Project for neurological disease research with a generous donation of $2 million.
Neurological diseases impact 3.6 million Canadians but remain a mystery. The care and research teams behind CHUM's SERVO Project believe that the use of artificial intelligence represents the key to propelling neurology to the next level, and that this change is necessary to achieve major progress. Artificial intelligence and the use of connected objects, in addition to the mega-database that will result, will thus enable a better understanding of neurological diseases to offer patients personalized treatments, tailored to their profiles and needs.
Thanks to the $2 million contribution, this unique Canadian project will benefit thousands of Quebecers impacted by neurological diseases such as epilepsy, Parkinson's disease, and multiple sclerosis, to name just a few.
Bombardier and the Bombardier, Beaudoin and Fontaine families are proud to contribute to the implementation of transformative projects that benefit the population. Through this generous donation, they hope to give wings to Quebec innovation.
''The CHUM's SERVO Project is a transformative project that will enable real breakthroughs in neurological research, permitting personalized care, thanks to the power of artificial intelligence. Alongside the Bombardier, Beaudoin, and Fontaine families, I am proud to lend my voice to this cause and make a positive contribution to patients' lives. A member of my family suffers from epilepsy, so I know first-hand the importance of providing the right treatment for every person with a neurological condition'', explains Éric Martel, President and CEO of Bombardier.
''Together with Bombardier, the Bombardier, Beaudoin, and Fontaine families are extremely proud to see such an innovative project being carried out in Quebec, and we are pleased to support this incredible initiative with a donation totalling $2 million. It is an honor to be a partner of the CHUM, which will carry the story of Quebec innovation around the world. We congratulate the researchers involved in the SERVO project, which will provide a better understanding of neurological diseases and improve the quality of life of many Quebecers'', says Laurent Beaudoin.
''The CHUM Foundation is extremely grateful to be able to count on the significant support of Bombardier as well as the Bombardier, Beaudoin, and Fontaine families, to finance projects like the CHUM's SERVO project, which brings hope to patients. Through their generous donations, they demonstrate their deep involvement in the evolution of Quebec research. They are regular supporters of many innovative causes in Quebec, and we are delighted to have them on board for this major project. The Foundation thanks them for their commitment to research and technological advancement at the CHUM'', says Pascale Bouchard, President and CEO of the CHUM Foundation.
Bombardier (BBD-B.TO) is a global leader in aviation, focused on designing, manufacturing, and servicing the world's most exceptional business jets. Bombardier's Challenger and Global aircraft families are renowned for their cutting-edge innovation, cabin design, performance, and reliability. Bombardier has a worldwide fleet of approximately 5,000 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments, and private individuals. Bombardier aircraft are also trusted around the world in government and military special-mission roles leveraging Bombardier Defense's proven expertise.
At the CHUM Foundation, we rally a community of committed donors around the CHUM, a leader in the healthcare system. With their support, we provide a complementary source of funding that drives innovation, accelerates technological development, and enables the CHUM to excel in care, research, and teaching, so that no patient is left behind.
https://fondationduchum.com/en/
SOURCE Fondation du CHUM
Marc Duchesne, [email protected], 514 277-3508
Share this article